Search Results

Joshua Gross were enthusiastic about the idea and jumped on board. Dylan Eiger , and Joshua Gross. We are very excited about this event.

Ross Cheloha About this episode Dr. Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Ross and I chatted about his work and transition to an independent investigator; join me to learn more Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr.

www.ecosystem.drgpcr.com/receptor-activation-and-signaling/germline-mutations-in-a-g-protein-identify-signaling-cross-talk-in-t-cells

aligned with strategy, not spreadsheets Set up clear deliverables across internal and CRO teams Keep cross-functional Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

In GPCR drug discovery, where complexity is the rule and timelines are tight, this kind of cross-functional

Cross-sector : Academia, biotech, pharma, CROs all in one room.

models, along with different cell culture systems, to understand the role of immune cell GPCRs and their cross-talk

Core themes: Strategic Planning for Biotech Growth Operational System Design (OS) Cross-functional Team

unexpected glucagon-derived peptide behavior How future metabolic therapies may evolve based on receptor cross-talk

Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

You will walk away with a deeper understanding of GPCR internalization, probe specificity, and the cross-disciplinary

He’s a strong advocate for cross-disciplinary thinking, mentoring young scientists, and building companies

collecting duct, we generated a collecting duct-specific GPR56 knockout (GPR56CD-KO) mouse model by crossing GPR56CD-KO mice were born at predicted Mendelian frequencies, appeared grossly indistinguishable from

Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses

be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses

mouse model (germline Tp53 deletion) with a second floxed allele under the control of Nestin-Cre was crossed

; Park, Christopher; Hattori, Takamitsu; Koide, Shohei; Placantonakis, Dimitris New York University Grossman of Medicine" About Dimitris Placantonakis "Dimitris Placantonakis is a neurosurgeon-scientist at NYU Grossman

In GPCR drug discovery, where complexity is the rule and timelines are tight, this kind of cross-functional